Senior Counsels Jason Drori and Simon Elliott contributed an article to IPPro Patents, “The PRICED Act: A Bold Attempt to Change the Biologics Market,” on August 17, 2016. The article examined the Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act proposed legislation that aims to reduce the market exclusivity period for new biologics from 12 to seven years in the United States. Drori and Elliott discussed how the PRICED Act may be a more direct threat to the biologics industry and risks upsetting a delicate balance.
Related Insights
February 10, 2026
Health Care Law Today
PBM Reform Cheat Sheet: Chart Comparing the Recent Rules for Group Plans
Key Takeaways: Within a one-week period, there were two actions at the federal level to increase pharmacy benefits manager (PBM)…
February 10, 2026
Foley Viewpoints
PBM Reform Cheat Sheet: Chart Comparing the Recent Rules for Group Plans
Key Takeaways: Within a one-week period, there were two actions at the federal level to increase pharmacy benefits manager (PBM)…
March 26, 2026
Events
Exploring the Subtleties and Safe Zones of Off-Label Communications — Part 2
Foley partner Kyle Faget, co-chair of the Medical Devices & Equipment Area of Focus within the firm’s Health Care & Life Sciences Sector, is speaking on the panel “Exploring the Subtleties and Safe Zones of Off-Label Communications — Part 2” during the American Conference Institute’s FDA Boot Camp program on Thursday, March 26.